218 related articles for article (PubMed ID: 34710286)
1. Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia.
Damato V; Papi C; Spagni G; Evoli A; Silvestri G; Masi G; Sabatelli E; Campetella L; McKeon A; Andreetta F; Riso V; Monte G; Luigetti M; Primiano G; Calabresi P; Iorio R
Eur J Neurol; 2022 Feb; 29(2):564-572. PubMed ID: 34710286
[TBL] [Abstract][Full Text] [Related]
2. Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.
Jones AL; Flanagan EP; Pittock SJ; Mandrekar JN; Eggers SD; Ahlskog JE; McKeon A
JAMA Neurol; 2015 Nov; 72(11):1304-12. PubMed ID: 26414229
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune Cerebellar Ataxia: Etiology and Clinical Characteristics of a Case Series from China.
Liu M; Ren H; Zhu Y; Fan S; Bai L; Wang J; Cui L; Guan H
Cerebellum; 2023 Jun; 22(3):379-385. PubMed ID: 35618871
[TBL] [Abstract][Full Text] [Related]
4. Inositol 1,4,5-trisphosphate receptor type 1 autoantibody (ITPR1-IgG/anti-Sj)-associated autoimmune cerebellar ataxia, encephalitis and peripheral neuropathy: review of the literature.
Jarius S; Bräuninger S; Chung HY; Geis C; Haas J; Komorowski L; Wildemann B; Roth C
J Neuroinflammation; 2022 Jul; 19(1):196. PubMed ID: 35907972
[TBL] [Abstract][Full Text] [Related]
5. [Usefulness of an anti-mouse cerebellar tissue-derived antigen antibody test in predicting immunotherapy efficacy in patients with idiopathic cerebellar ataxia].
Ohtomo T; Ogino S; Yanai S; Nakayama S; Yajima R; Sugawara M; Yamada J; Aizawa H; Taguchi T; Nanri K
Rinsho Shinkeigaku; 2022 Feb; 62(2):112-122. PubMed ID: 35095045
[TBL] [Abstract][Full Text] [Related]
6. A retrospective study of autoimmune cerebellar ataxia over a 20-year period in a single institution.
Kudo A; Yaguchi H; Tanaka K; Kimura A; Yabe I
J Neurol; 2024 Jan; 271(1):553-563. PubMed ID: 37610447
[TBL] [Abstract][Full Text] [Related]
7. Autoantibodies against eukaryotic translation elongation factor 1 delta in two patients with autoimmune cerebellar ataxia.
Guo L; Ren H; Fan S; Chao X; Liu M; Guan H; Wang J
Front Immunol; 2023; 14():1289175. PubMed ID: 38332912
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients.
Iorio R; Damato V; Evoli A; Gessi M; Gaudino S; Di Lazzaro V; Spagni G; Sluijs JA; Hol EM
J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):138-146. PubMed ID: 28951498
[TBL] [Abstract][Full Text] [Related]
9. 'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook.
Jarius S; Wildemann B
J Neuroinflammation; 2015 Sep; 12():168. PubMed ID: 26377319
[TBL] [Abstract][Full Text] [Related]
10. Neurological Autoimmunity Associated With Homer-3 Antibody: A Case Series From China.
Liu M; Ren H; Fan S; Zhang W; Xu Y; Zhao W; Guan H;
Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34580182
[TBL] [Abstract][Full Text] [Related]
11. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association.
Saiz A; Blanco Y; Sabater L; González F; Bataller L; Casamitjana R; Ramió-Torrentà L; Graus F
Brain; 2008 Oct; 131(Pt 10):2553-63. PubMed ID: 18687732
[TBL] [Abstract][Full Text] [Related]
12. Long-term clinical follow-up of a patient with non-paraneoplastic cerebellar ataxia associated with anti-mGluR1 autoantibodies.
Yoshikura N; Kimura A; Fukata M; Fukata Y; Yokoi N; Harada N; Hayashi Y; Inuzuka T; Shimohata T
J Neuroimmunol; 2018 Jun; 319():63-67. PubMed ID: 29685291
[TBL] [Abstract][Full Text] [Related]
13. Septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia.
Miske R; Scharf M; Borowski K; Rieckhoff N; Teegen B; Denno Y; Probst C; Guthke K; Didrihsone I; Wildemann B; Ruprecht K; Komorowski L; Jarius S
J Neuroinflammation; 2023 Mar; 20(1):88. PubMed ID: 36997937
[TBL] [Abstract][Full Text] [Related]
14. Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy.
Ariño H; Gresa-Arribas N; Blanco Y; Martínez-Hernández E; Sabater L; Petit-Pedrol M; Rouco I; Bataller L; Dalmau JO; Saiz A; Graus F
JAMA Neurol; 2014 Aug; 71(8):1009-16. PubMed ID: 24934144
[TBL] [Abstract][Full Text] [Related]
15. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.
Shams'ili S; Grefkens J; de Leeuw B; van den Bent M; Hooijkaas H; van der Holt B; Vecht C; Sillevis Smitt P
Brain; 2003 Jun; 126(Pt 6):1409-18. PubMed ID: 12764061
[TBL] [Abstract][Full Text] [Related]
16. 'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 2: Anti-PKC-gamma, anti-GluR-delta2, anti-Ca/ARHGAP26 and anti-VGCC.
Jarius S; Wildemann B
J Neuroinflammation; 2015 Sep; 12():167. PubMed ID: 26377184
[TBL] [Abstract][Full Text] [Related]
17. Low-Titre GAD Antibody-Associated Late-Onset Cerebellar Ataxia with a Significant Clinical Response to Intravenous Immunoglobulin Treatment.
Petrijan T; Menih M
Cerebellum; 2017 Aug; 16(4):868-871. PubMed ID: 28321713
[TBL] [Abstract][Full Text] [Related]
18. The Scale for Assessment and Rating of Ataxia Is Reliable and Valid in the Telehealth Setting for Patients With Cerebellar Ataxia.
Reoli R; Therrien A; Millar J; Hill N; Varghese R; Roemmich R; Whitall J; Bastian A; Keller J
Phys Ther; 2024 Mar; 104(3):. PubMed ID: 38051602
[TBL] [Abstract][Full Text] [Related]
19. [Cerebellar Ataxia and Autoantibodies].
Nanri K; Yoshikura N; Kimura A; Nakayama S; Otomo T; Shimohata T; Terashi H; Sato T; Yamada J
Brain Nerve; 2018 Apr; 70(4):371-382. PubMed ID: 29632285
[TBL] [Abstract][Full Text] [Related]
20. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
Levite M
J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
